DNDi Annual Report 2013
August 2014   |   View Online

Dear colleague,

Summer greetings from DNDi!

I am pleased to share with you DNDi’s Annual report 2013 ‘A Decade of R&D for Neglected Patients’. Indeed, the year 2013 marked DNDi’s 10-year anniversary and provided us the opportunity to reflect not only on our own work, achievements, and lessons learned, but also on the broader landscape of research and development (R&D) for neglected diseases and how it has evolved since DNDi was launched in 2003.

A recent analysis of the R&D pipeline for neglected diseases showed that the past ten years have seen a small increase in the percentage of drugs and vaccines approved for neglected diseases, primarily in repurposing or combining existing drugs. Truly new drugs will take more time and resources to make their way to the end of the development pipeline. This is part of our common challenge today.

Over the past decade, DNDi has not only delivered six improved treatments for urgent needs of patients, but has also consolidated a solid portfolio of entirely new clinical candidates. So far, 12 new chemical entities are progressing through our drug development pipeline.

On behalf of the entire DNDi team, I want to thank you sincerely for your support, encouragement, and input into our work over the past 10 years to bring new treatments to neglected patients. We look forward to another exciting and fruitful decade of partnering to deliver the best science for the most neglected.
Best regards,

Dr Bernard Pécoul
Executive Director, DNDi


A Decade of R&D for Neglected Patients
Overview & Governance
R&D Model, Strategy & Portfolio
Strengthening Existing Capacities
Advocacy, Communications & Fundraising
Financial Report
Photo credit: Don Paul/DNDi
Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2014 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202

Add us to your address book

unsubscribe from this list    update subscription preferences